Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT07229729

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2025-12-01

300

Participants Needed

1

Research Sites

201 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

CONDITIONS

Official Title

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntarily agree to participate and provide written informed consent
  • Aged between 18 and 70 years old inclusive
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Have adequate organ function
  • Women of childbearing age must have a negative pregnancy test and agree to use effective contraception, as must male partners of women of childbearing age
Not Eligible

You will not qualify if you...

  • Have active, known, or suspected autoimmune disease
  • Have had cancers other than non-small cell lung cancer within the past 5 years
  • Have or are suspected to have pneumonitis, interstitial lung disease, or serious lung diseases affecting lung function
  • Have a significant history of cardiovascular or cerebrovascular disease or bleeding disorders
  • Have experienced arteriovenous thrombotic events
  • Have a known history of HIV infection
  • Have active Hepatitis B or Hepatitis C infection
  • Are allergic to any study treatment drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510080

Actively Recruiting

Loading map...

Research Team

J

Junli Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here